[go: up one dir, main page]

DE60042487D1 - Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine - Google Patents

Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine

Info

Publication number
DE60042487D1
DE60042487D1 DE60042487T DE60042487T DE60042487D1 DE 60042487 D1 DE60042487 D1 DE 60042487D1 DE 60042487 T DE60042487 T DE 60042487T DE 60042487 T DE60042487 T DE 60042487T DE 60042487 D1 DE60042487 D1 DE 60042487D1
Authority
DE
Germany
Prior art keywords
antagonists
composition
mmp
beta1 integrins
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042487T
Other languages
English (en)
Inventor
Peter C Brooks
Loubna Hassanieh
Dorothy Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE60042487D1 publication Critical patent/DE60042487D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60042487T 1999-07-13 2000-07-13 Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine Expired - Lifetime DE60042487D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14358199P 1999-07-13 1999-07-13
US15249599P 1999-09-02 1999-09-02
PCT/US2000/019095 WO2001004157A2 (en) 1999-07-13 2000-07-13 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS

Publications (1)

Publication Number Publication Date
DE60042487D1 true DE60042487D1 (de) 2009-08-13

Family

ID=26841194

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042487T Expired - Lifetime DE60042487D1 (de) 1999-07-13 2000-07-13 Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine

Country Status (10)

Country Link
US (1) US7566449B2 (de)
EP (1) EP1203025B1 (de)
JP (1) JP2003508352A (de)
CN (1) CN1379685A (de)
AT (1) ATE435031T1 (de)
AU (1) AU783019B2 (de)
CA (1) CA2379373A1 (de)
DE (1) DE60042487D1 (de)
ES (1) ES2327812T3 (de)
WO (1) WO2001004157A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041787B2 (en) 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
JP2006527740A (ja) * 2003-06-19 2006-12-07 シーティーティー キャンサー ターゲッティング テクノロジーズ オイ 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
US8147836B2 (en) 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
EP2650017A3 (de) * 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Alpha-5-beta-1-Antikörper und deren Verwendungen
CA2717803A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
EP2262529A4 (de) * 2008-03-03 2013-05-08 Dyax Corp Metalloproteinase-9-bindungsproteine
WO2011028883A2 (en) * 2009-09-03 2011-03-10 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
KR101518144B1 (ko) 2010-08-27 2015-05-28 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
EP2819697A4 (de) 2012-02-29 2016-03-09 Gilead Biologics Inc Antikörper gegen matrix-metalloproteinase-9
IN2014DN08011A (de) 2012-02-29 2015-05-01 Gilead Biologics Inc

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
AU5558394A (en) 1992-12-04 1994-07-04 Shriners Hospitals For Crippled Children Immunoassay for the measurement of collagen cleavage in cartilage
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
US5541295A (en) * 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
FI960392L (fi) 1993-07-28 1996-01-29 Boehringer Mannheim Gmbh Immunomääritys kollageenin tai kollageenifragmenttien osoittamiseksi
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5763272A (en) * 1994-12-23 1998-06-09 Boehringer Mannheim Gmbh Hybridoma for producing antibody for collagen I
AU3304597A (en) 1996-05-23 1997-12-09 Shriners Hospital For Children Cartilage type ii collagen as an angiogenic factor
US6492508B1 (en) 1996-06-03 2002-12-10 United States Surgical Corp. A Division Of Tyco Healthcare Group Nucleic acids encoding extracellular matrix proteins
GB9702252D0 (en) 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay
JP2001512143A (ja) * 1997-07-31 2001-08-21 メトラ バイオシステムズ， インコーポレイテッド コラーゲン−ペプチドアッセイ法
US6030792A (en) * 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
ATE423570T1 (de) * 1998-05-08 2009-03-15 Univ California Verfahren zum nachweis und hemmung der angiogenese
US7101975B1 (en) * 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins

Also Published As

Publication number Publication date
JP2003508352A (ja) 2003-03-04
WO2001004157A2 (en) 2001-01-18
ES2327812T3 (es) 2009-11-04
AU6344700A (en) 2001-01-30
US7566449B2 (en) 2009-07-28
US20060062777A1 (en) 2006-03-23
WO2001004157A3 (en) 2001-05-17
EP1203025A2 (de) 2002-05-08
ATE435031T1 (de) 2009-07-15
CN1379685A (zh) 2002-11-13
CA2379373A1 (en) 2001-01-18
AU783019B2 (en) 2005-09-15
WO2001004157A9 (en) 2002-07-25
EP1203025B1 (de) 2009-07-01

Similar Documents

Publication Publication Date Title
DE60042487D1 (de) Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
ATE439369T1 (de) Methode und zubereitung zur hemmung von angiogenese
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
WO2007012004A3 (en) Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
KR960022562A (ko) 항-αV-인터그린 모노크로날 항체
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE60121808D1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
WO2001007595A3 (en) Novel fibroblast growth factor and nucleic acids encoding same
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
ATE514715T1 (de) Monoklonaler anti-met-antikörper, fragmente und vektoren davon zur behandlung von tumoren und entsprechende produkte
WO2006087637A3 (en) Anti her2/neu antibody
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
ATE494301T1 (de) Alpha-fetoprotein-peptide und ihre verwendung
DE69810513D1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
ATE290881T1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE69932834D1 (de) Chi-Conotoxinpeptide als Inhibitoren neuronaler Amintransporter
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8330 Complete renunciation